Not only a time-saving approach: Is it the time of subcutaneous formulation for daratumumab administration?

Treating multiple myeloma in the era of new drugs: What is the right choice?

“…Furthermore, the introduction of its subcutaneous formulation resulted in a time-saving approach, optimizing hospital admission of patients and reducing workload of hospital pharmacy, especially in the era of coronavirus disease 2019. 12 Undoubtedly, in the next few years longer follow-up data from ongoing clinical studies and the introduction of new molecules (i.e., new immunomodulatory drugs, CELMoDs like iberdomide; BCMA-and non-BCMA directed bispecific antibodies), [13][14][15] as well as the introduction of the CAR-T technology, could clarify these aspects in order to optimize and "tailor" the treatment choice. This, in turn, will improve the outcome of each patient, with the ultimate goal of finding the cure for MM.…”

“…Furthermore, the introduction of its subcutaneous formulation resulted in a time-saving approach, optimizing hospital admission of patients and reducing workload of hospital pharmacy, especially in the era of coronavirus disease 2019. 12…”